Andrea Mosca1, Renata Paleari2, Anna Carobene3, Cas Weykamp4, Ferruccio Ceriotti3. 1. Centro per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Dip. di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, Milano, Italy. Electronic address: andrea.mosca@unimi.it. 2. Centro per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Dip. di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, Milano, Italy. 3. Laboratorio di Standardizzazione, Servizio Medicina di Laboratorio, Ospedale San Raffaele, Milano, Italy. 4. Department of Clinical Chemistry, Location Queen Beatrix Hospital, Winterswijk, The Netherlands; European Reference Laboratory, Location Queen Beatrix Hospital, Winterswijk, The Netherlands.
Abstract
BACKGROUND: The determination of glycated hemoglobin is a key indicator for the management of diabetic patients. A reference measurement system for its determination is available and IVD manufacturers should have aligned their assay to this system. METHODS: Two fresh blood samples were distributed by courier to 206 Italian laboratories asking for the determination of their HbA1c concentration. Target HbA1c values were assigned by the IFCC reference measurement procedure. RESULTS: From 193 laboratories using analytical systems from five manufacturers (Bio-Rad Laboratories, A. Menarini Diagnostics, Roche Diagnostics, Sebia and Tosoh), we obtained a global variability of 5.3% (in terms of CV) and of 3.8% at an HbA1c value of 37.4 mmol/mol (sample 1) and 62.0 mmol/mol (sample 2), respectively. With a goal for the allowable total error (TE) of 6.0%, 70% and 77% of the participants met this criterion for samples 1 and 2, respectively. Inter-laboratory CVs, were between 3.3 and 5.0% and between 2.2 and 3.7% for samples 1 and 2, respectively. Tosoh users registered the smallest inter-laboratory CV in sample 1, and Sebia's in sample 2. With regard to trueness, all methods had a mean bias of ≤ 2.8% with respect to the target values, with the exception of Tosoh (bias of + 6.1 and + 5.8%, for samples 1 and 2, respectively). CONCLUSION: These results are in good agreement with those obtained by the CAP 2014 GH2-A survey, suggesting then that still there is an urgent need for improving a significant part of the methods currently used to measure HbA1c.
BACKGROUND: The determination of glycated hemoglobin is a key indicator for the management of diabeticpatients. A reference measurement system for its determination is available and IVD manufacturers should have aligned their assay to this system. METHODS: Two fresh blood samples were distributed by courier to 206 Italian laboratories asking for the determination of their HbA1c concentration. Target HbA1c values were assigned by the IFCC reference measurement procedure. RESULTS: From 193 laboratories using analytical systems from five manufacturers (Bio-Rad Laboratories, A. Menarini Diagnostics, Roche Diagnostics, Sebia and Tosoh), we obtained a global variability of 5.3% (in terms of CV) and of 3.8% at an HbA1c value of 37.4 mmol/mol (sample 1) and 62.0 mmol/mol (sample 2), respectively. With a goal for the allowable total error (TE) of 6.0%, 70% and 77% of the participants met this criterion for samples 1 and 2, respectively. Inter-laboratory CVs, were between 3.3 and 5.0% and between 2.2 and 3.7% for samples 1 and 2, respectively. Tosoh users registered the smallest inter-laboratory CV in sample 1, and Sebia's in sample 2. With regard to trueness, all methods had a mean bias of ≤ 2.8% with respect to the target values, with the exception of Tosoh (bias of + 6.1 and + 5.8%, for samples 1 and 2, respectively). CONCLUSION: These results are in good agreement with those obtained by the CAP 2014 GH2-A survey, suggesting then that still there is an urgent need for improving a significant part of the methods currently used to measure HbA1c.